Immunoassays remain a cornerstone of bioanalytical testing across biopharmaceutical research, development, and manufacturing. They are widely used to quantify biologics, assess pharmacokinetics (PK), measure biomarkers, and monitor immunogenicity.
As therapeutic modalities evolve, spanning monoclonal antibodies, bispecifics, recombinant proteins, and advanced modalities like cell and gene therapies, the demands on bioanalytical methods continue to grow. Today’s assays must deliver high-quality, reproducible data quickly, often from limited sample volumes and complex biological matrices.
At the same time, biopharma organizations are under increasing pressure to accelerate timelines while maintaining regulatory compliance. This is driving the adoption of automated, miniaturized immunoassay technologies that reduce hands-on time, improve consistency, and enable more efficient data generation.
In this article, we explore how to:
Generate robust, high-quality immunoassay data
Address common development and matrix-related challenges
Maximize productivity while minimizing sample and reagent use
Modern drug development, especially in areas like cell and gene therapy, requires bioanalytical methods that can keep pace with compressed timelines and complex study designs.
Achieving this depends on three key factors:
High-quality reagents
Optimized assay design
Automation
The foundation of any immunoassay is the performance of its reagents. High-affinity, highly specific antibodies are essential for achieving the sensitivity, selectivity, and precision required for regulated bioanalysis.
Using well-characterized reagents, whether in ready-to-use kits or optimized assay protocols, can significantly reduce development time and improve consistency. Equally important is selecting a platform that supports efficient assay development, validation, and transfer between laboratories.
Automation has become central to modern immunoassay workflows. By reducing manual pipetting and handling steps, automated systems help:
Improve precision and reproducibility
Reduce operator-dependent variability
Minimize errors and rework
Increase throughput
Free up time for data analysis
Automation also supports standardization across sites, making it easier to transfer assays between pharma companies and CROs. With well-designed workflows, it is increasingly possible to achieve the performance needed for single-replicate (singlicate) analysis when supported by proper validation.
Working with biological samples introduces variability and complexity. Matrix effects, interference, and cross-reactivity can all impact assay performance.
Managing matrix interference
Interference can arise from endogenous proteins, binding partners, or changes in sample composition. Early assessment during method development is essential, including evaluation of:
Parallelism and dilution linearity
Spike recovery
Matrix effects and blocking strategies
Variability across study samples
While dilution is often used to reduce interference, it can also reduce sensitivity. An alternative approach is to limit interaction time between sample components and assay reagents, favoring high-affinity binding and reducing non-specific interactions
Reducing cross-reactivity
Antibody specificity is critical. Cross-reactivity remains one of the most common challenges in immunoassay development, particularly in complex matrices. Careful antibody selection, often combining monoclonal capture antibodies with well-characterized detection reagents, helps improve assay specificity and robustness.
Sample availability is often limited, especially in:
Preclinical studies aligned with 3R principles
Pediatric or rare disease studies
Cell and gene therapy applications
Miniaturized immunoassays, operating at the nanoliter scale, allow researchers to generate more data from smaller sample volumes while also reducing reagent consumption. This not only improves efficiency but can enable study designs that were previously difficult or impossible, such as longitudinal sampling from the same subject.
A common source of inefficiency is the need to repeat assays due to out-of-range samples. Platforms with broad dynamic range and high precision help reduce the need for dilution series and repeat analysis, improving turnaround time and overall productivity.
Multiplex immunoassays are often considered a way to increase throughput and conserve samples. While they can offer advantages, they also introduce complexity:
Increased risk of cross-reactivity
Challenges in aligning dynamic ranges across analytes
Longer development and optimization times
In many cases, running miniaturized singleplex assays in parallel can provide a more flexible and efficient alternative, especially when supported by automation.
Running multiple singleplex assays in parallel combines the benefits of simplicity and efficiency:
High specificity with no cross-talk between assays
Flexible assay design tailored to each analyte
Efficient use of sample through miniaturization
Reduced development complexity
With automated platforms, this approach enables high-throughput analysis while maintaining strong data quality and reproducibility.
As biopharma continues to evolve, so do the expectations for bioanalytical methods. Immunoassays must now deliver speed, reliability, and efficiency without compromising data quality or compliance.
Key enablers of success include:
High-quality, well-characterized reagents
Thoughtful assay design and early challenge mitigation
Automation to improve consistency and throughput
Miniaturization to maximize data from limited samples
Flexible workflows that support scalable development
By combining these elements, laboratories can build immunoassay workflows that not only meet today’s demands but are ready for the next generation of biotherapeutics.